Please assess the completion status of the following clinical trial:

Trial Title: Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage 2 infection with Trypanosoma brucei gambiense diagnosed within the previous 14 days, as defined by either of the following: (i) Presence of trypanosomes in blood or lymph node fluid and WBC count in CSF \> 5 / mm3, or (ii) Presence of trypanosomes in the CSF with any CSF WBC count~* Residence in the study area~* Written informed consent (to be obtained from parent/guardian for children under 18 years and patients with impaired cognition)~Exclusion Criteria:~* Pregnancy or clinical history suggestive thereof~* Weight \< 10 Kg~* History of any HAT treatment within the previous 24 months~* Inability to undergo hospitalisation or attend follow-up visits during the 24 months following discharge~* Severe anemia (Hb\< 5g/dl)~* Active tuberculosis (sputum positive)~* HIV positive (if patient has been tested and results are known)~* Severe renal or hepatic failure~* Bacterial or cryptococcal meningitis~* Other severe underlying diseases upon admission~* Refugee status

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).